[Prolactin in connective tissue diseases].
This paper presents interactions between prolactin (PRL) and the immune system. We describe the role of PRL in the pathogenesis of rheumatic diseases, particularly connective tissue diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), primary Sjögren's syndrome, systemic sclerosis, polymyalgia rheumatica, and seronegative arthritis. We present current opinion on the mechanisms responsible for hyperprolactinemia in SLE patients and the association between hyperprolactinemia and SLE activity and organ involvement. The role of dopamine receptor agonists in the treatment of connective tissue diseases is discussed.
Parada-Turska
Jolanta
J
Katedra i Klinika Reumatologii i Układowych Chorób Tkanki Łacznej Akademii Medycznej im. prof. Feliksa Skubiszewskiego w Lublinie.
Targońska-Stepniak
Bozena
B
Majdan
Maria
M
D000818:Animals; D001327:Autoimmune Diseases / Q000276:immunology*; D015897:Comorbidity; D003240:Connective Tissue Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology*; D018491:Dopamine Agonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000453:epidemiology / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000453:epidemiology / Q000276:immunology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000276:immunology; D011388:Prolactin / Q000235:genetics / Q000276:immunology*; D012216:Rheumatic Diseases / Q000453:epidemiology / Q000276:immunology
D018491:Dopamine Agonists; D011388:Prolactin